Healthy Living/WellnessFDA Approves Genentech Drug Alecensa For ALK-Positive Lung Cancer Genentech's lung cancer drug Alecensa received FDA's conditional approval for the treatment of ALK-positive lung cancer. Alecensa was found to reduce lung tumors of 44 percent of the 138 patients with benefits lasting an average of 11 months.by Katherine Derla
Healthy Living/WellnessDoctors Dispute FDA Ruling On Device To Remove Uterine Fibroidsby Angela Laguipo
Healthy Living/WellnessGame Changing Syringe That Plugs Bullet Wounds In 20 Seconds Gets FDA Approval For Civilian Useby Alexandra Burlacu
Healthy Living/WellnessNut Butter Tied To Salmonella Outbreak That Sickened 11 In Nine Statesby Angela Laguipo
Healthy Living/WellnessMontana Woman Files Lawsuit Against Costco, Supplier In E. Coli Outbreakby Angela Laguipo
Healthy Living/WellnessFDA Declines Approval Of Opdivo Drug For Expanded Use As Metastatic Melanoma Treatmentby Katherine Derla
Healthy Living/WellnessFDA Panel Not Persuaded By Effectiveness Of BioMarin Duchenne Muscular Dystrophy Drugby Angela Laguipo
Healthy Living/WellnessFDA Seeks Public Comment On Meaning Of Word 'Natural' On Food Labelsby Katherine Derla
Apple to Release iOS 18.2 Earlier This December, Featuring Siri's ChatGPT, Apple Intelligence Upgrades